Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured ...

FDA’s top drug regulator resigns after federal officials probe ‘serious concerns’

A federal spokesperson said Dr. George Tidmarsh left the agency after federal lawyers began looking into “serious concerns about his personal conduct,” ...

FDA says clinical data for UniQure's Huntington's disease therapy not adequate

UniQure, said on Monday its experimental gene therapy for Huntington's disease does not have adequate clinical data to ...

Lilly to Build $3 Billion Dutch Plant to Boost Weight-Loss Pill Production

Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other ...

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today ...

Listeria outbreak: Many people dead after consuming recalled pasta meals - check yours immediately

A listeria outbreak has claimed seven lives and sickened 27 people. The contamination is linked to recalled pasta meals sold ...
STAT

Uniqure’s FDA submission for its Huntington’s disease therapy thrown into question

In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now ...